Recent Updates
Recently added Catalysts
OCGN

ocgn-20201106xex991cd Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Nov 2020 Forward Looking Statement This presentation contains forward-looking statements that involve

Friday, November 6, 2020 1 min read
Key Takeaway: Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Nov 2020 Ocugen's Modifier Gene Therapy Platform Breakthrough Technology Designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 5

Full Press Release Details

Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: Nov 2020
Ocugen's Modifier Gene Therapy Platform Breakthrough Technology Designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 5
OCU200: Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Wet Age-Related Macular Degeneration (Wet AMD) Novel Biologic Offering Benefits Beyond Anti-VEGF 16
A Bold Vision to Cure Blindness Diseases with Gene Therapies For more information, contact: IR@ocugen.com
Tags: OCGN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Nov 6, 2020